Jeanna L. Welborn
Hematology Oncology | Medical Genetics | Hematology
3850 G St
Merced, CA 95340
Merced, CA 95340
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 11, 2026
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: December 17, 2024
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 23, 2024
CML and the WHO: Why?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 12, 2023
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 19, 2023
Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.
Journal: Leukemia research
Published: February 21, 2022
Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?
Journal: CA: a cancer journal for clinicians
Published: June 17, 2020
Germline mutations predisposing to melanoma.
Journal: Journal of cutaneous pathology
Published: December 20, 2019
A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia.
Journal: American journal of hematology
Published: May 01, 2019
Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia.
Journal: Human pathology (New York)
Published: July 27, 2016
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Journal: British journal of haematology
Published: August 12, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026